Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
Gomez-Iturriaga A, Casquero F, Urresola A, Ezquerro A, Lopez JI, Espinosa JM, Minguez P, Llarena R, Irasarri A, Bilbao P, Crook J. Gomez-Iturriaga A, et al. Radiother Oncol. 2016 Apr;119(1):91-6. doi: 10.1016/j.radonc.2016.02.004. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900090 Clinical Trial.
Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D, Casquero F, Espinosa JM, Perez F, Minguez P, Martinez-Indart L, Suarez F, Gonzalez A, Cacicedo J, San Miguel I, Maleta A, Gomez-Caamaño A, Bilbao P, Gomez-Iturriaga A. Büchser D, et al. Radiother Oncol. 2019 Jun;135:13-18. doi: 10.1016/j.radonc.2019.02.018. Epub 2019 Mar 5. Radiother Oncol. 2019. PMID: 31015158
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Achard V, et al. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. Radiother Oncol. 2022. PMID: 35476942 Free article. Clinical Trial.
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.
Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, Ingrosso G, Alongi F, Aluwini S, Arcangeli S, Blanchard P, Conde Moreno A, Couñago F, Créhange G, Dirix P, Gomez Iturriaga A, Guckenberger M, Pasquier D, Sargos P, Scorsetti M, Supiot S, Tree AC, Zapatero A, Le Guevelou J, Ost P, Belka C. Zilli T, et al. Radiother Oncol. 2022 Nov;176:199-207. doi: 10.1016/j.radonc.2022.10.005. Epub 2022 Oct 10. Radiother Oncol. 2022. PMID: 36228761 Free article.
Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
Gomez-Iturriaga A, Zaragoza L, Valverde I, Perez Azorin F, Santos-Zorrozua B, Guerrero JA, Couñago F, Cacicedo J, Marban M, Santana S, Mascarell C, Novo E, Fernandez R, Garcia-Olaverri J, Urresola A, Ezquerro A, Büchser D. Gomez-Iturriaga A, et al. Radiother Oncol. 2024 Jan;190:110024. doi: 10.1016/j.radonc.2023.110024. Epub 2023 Nov 22. Radiother Oncol. 2024. PMID: 37995851
67 results